Stock Analysis on Net

Cigna Group (NYSE:CI)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 27, 2025.

Analysis of Inventory

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Inventory Disclosure

Cigna Group, balance sheet: inventory

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Prescription drugs and medical supplies
Inventories

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Trend Analysis of Prescription Drugs and Medical Supplies / Inventories

The data exhibits a consistent upward trend in the value of prescription drugs and medical supplies, which is identical to the inventories value over the analyzed period from 2020 to 2024.

Starting at US$3,165 million in 2020, the value increased to US$3,722 million in 2021, representing a growth of approximately 17.6%. The upward trend accelerated in subsequent years, reaching US$4,777 million in 2022, a significant rise of about 28.4% from the previous year.

In 2023, a further increase to US$5,645 million was recorded, reflecting a growth rate of around 18.2%, while the latest figure for 2024 shows continued expansion to US$6,692 million, which is an 18.5% increase compared to 2023.

Overall, the data indicates strong and steady growth in the inventories, specifically prescription drugs and medical supplies, over the five-year period. The consistent rise suggests increasing investment or accumulation in these assets, potentially aligned with business expansion, rising demand, or strategic stockpiling.